Antibacterial prophylaxis with ciprofloxacin for patients with multiple myeloma and lymphoma undergoing autologous haematopoietic cell transplantation: a quasi-experimental single-centre before-after study

Autor: Yeshurun, M., Vaxman, I., Shargian, L., Yahav, D., Bishara, J., Pasvolsky, O., Wolach, O., Lahav, M., Gurion, R., Magen, H., Vidal, L., Herscovici, C., Peck, A., Moshe, M., Sela-Navon, M., Naparstek, E., Raanani, P., Rozovski, U.

Publikováno v: In Clinical Microbiology and Infection July 2018 24(7):749-754

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Autor: Dimopoulos, M.A. Richardson, P.G. Bahlis, N.J. Grosicki, S. Cavo, M. Beksaç, M. Legieć, W. Liberati, A.M. Goldschmidt, H. Belch, A. Magen, H. Larocca, A. Laubach, J.P. Petrucci, M.T. Reece, D. White, D. Mateos, M.-V. Špička, I. Lazaroiu, M. Berdeja, J. Kaufman, J.L. Jou, Y.-M. Ganetsky, A. Popa McKiver, M. Lonial, S. Weisel, K. ELOQUENT-1 investigators

BACKGROUND: Elotuzumab plus lenalidomide and dexamethasone has shown improved progression-free and overall survival versus lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. We aimed to assess these regimens in p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::418814b244db6b2aeca1aa0a25decc0e
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3220220

Long-term Implications of Breast Cancer on Upper Extremity Functioning, Participation and Perceived Quality of Life

Autor: Langer, D, Magen, H, Bar-Haim Erez, A

Publikováno v: 14th Triennial Congress of the International Federation of Societies for Surgery of the Hand (IFSSH), 11th Triennial Congress of the International Federation of Societies for Hand Therapy (IFSHT), 11th Triennial Congress of the International Federation of Societies for Hand Therapy (IFSHT); 20190617-20190621; Berlin; DOCIFSHT19-1131 /20200206/

Objective: The objectives of the study were: to evaluate the long-term implications of breast cancer on upper extremity function, participation and perceived quality of life (QoL) among Israeli women; to examine the use of rehabilitation services dur

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04acaafbdc37ee9f1b110644118696dc

Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

Autor: Dimopoulos, M.A. Lonial, S. White, D. Moreau, P. Weisel, K. San-Miguel, J. Shpilberg, O. Grosicki, S. Špička, I. Walter-Croneck, A. Magen, H. Mateos, M.-V. Belch, A. Reece, D. Beksac, M. Spencer, A. Oakervee, H. Orlowski, R.Z. Taniwaki, M. Röllig, C. Einsele, H. Matsumoto, M. Wu, K.L. Anderson, K.C. Jou, Y.-M. Ganetsky, A. Singhal, A.K. Richardson, P.G.

Prolonging overall survival (OS) remains an unmet need in relapsed or refractory multiple myeloma (RRMM). In ELOQUENT-2 (NCT01239797), elotuzumab plus lenalidomide/dexamethasone (ERd) significantly improved progression-free survival (PFS) versus lena

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::39b07bb371bcfd579fbab9815699820d
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3103936

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma : a cytogenetic subgroup analysis of POLLUX

Autor: Kaufman, J. L., Dimopoulos, M., White, D., Benboubker, L., Cook, G., Leiba, M., Morton, J., Joy Ho, P., Kim, K., Takezako, N., Moreau, P., Sutherland, H. J., Magen, H., Iida, S., Kim, J. S., Miles Prince, H., Cochrane, T., Oriol, Albert, Bahlis, N. J., Chari, A., O'Rourke, L., Trivedi, S., Casneuf, T., Krevvata, M., Ukropec, J., Kobos, R., Avet-Loiseau, H., Usmani, S. Z., San-Miguel, J., Universitat Autònoma de Barcelona

Publikováno v: Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Blood Cancer Journal, Vol 10, Iss 11, Pp 1-10 (2020)
Blood Cancer Journal
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

High cytogenetic risk abnormalities confer poor outcomes in multiple myeloma patients. In POLLUX, daratumumab/lenalidomide/dexamethasone (D-Rd) demonstrated significant clinical benefit versus lenalidomide/dexamethasone (Rd) in relapsed/refractory mu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf52c1b21c245ed4d385bb3826621820
https://ddd.uab.cat/record/236598